Abstract
Hepatitis C virus represents a major global health problem, with approximately 3% of the world population infected. Immune-response modifiers represent the standard of care, given the lack of approved antiviral agents having direct activity against the viral proteins. Although in recent years, improvements in therapy have been attained by combined treatment with pegylated interferon and ribavirin, the discovery and development of next-generation small molecule and biologic agents is ongoing. Several of these newer therapeutics are focused on modulating Toll-like receptors, interferon-alpha signaling, and the pro-inflammatory cytokine balance. A comprehensive account of the lead compounds in development, the bioassays used for optimization of these immune response modifiers and their clinical status is presented.
Keywords: Imiquimod, isatoribine, cytosine-guanine oligonucleotides (CpG), immunomodulatory oligonucleotides (IMOs), toll-like receptors (TLR), inteferon (IFN)
Mini-Reviews in Medicinal Chemistry
Title: Small Molecule and Biologic Modulators of the Immune Response to Hepatitis C Virus
Volume: 6 Issue: 5
Author(s): M. L. Mbow, A. Eaton-Bassiri, W. G. Glass, A. M. Del Vecchio and R. T. Sarisky
Affiliation:
Keywords: Imiquimod, isatoribine, cytosine-guanine oligonucleotides (CpG), immunomodulatory oligonucleotides (IMOs), toll-like receptors (TLR), inteferon (IFN)
Abstract: Hepatitis C virus represents a major global health problem, with approximately 3% of the world population infected. Immune-response modifiers represent the standard of care, given the lack of approved antiviral agents having direct activity against the viral proteins. Although in recent years, improvements in therapy have been attained by combined treatment with pegylated interferon and ribavirin, the discovery and development of next-generation small molecule and biologic agents is ongoing. Several of these newer therapeutics are focused on modulating Toll-like receptors, interferon-alpha signaling, and the pro-inflammatory cytokine balance. A comprehensive account of the lead compounds in development, the bioassays used for optimization of these immune response modifiers and their clinical status is presented.
Export Options
About this article
Cite this article as:
Mbow L. M., Eaton-Bassiri A., Glass G. W., Del Vecchio M. A. and Sarisky T. R., Small Molecule and Biologic Modulators of the Immune Response to Hepatitis C Virus, Mini-Reviews in Medicinal Chemistry 2006; 6 (5) . https://dx.doi.org/10.2174/138955706776876195
DOI https://dx.doi.org/10.2174/138955706776876195 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design Curcumin Loaded and Co-loaded Nanosystems: A Review from a Biological Activity Enhancement Perspective
Pharmaceutical Nanotechnology Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Estrogens as Potential Therapeutic Agents in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) Treatment of Viral Encephalitis
Central Nervous System Agents in Medicinal Chemistry CD26: A Multi-Purpose Pharmacological Target
Current Clinical Pharmacology Small Molecule Inhibitors of PKCθ as Potential Antiinflammatory Therapeutics
Current Topics in Medicinal Chemistry Negative Regulation of TCR Signaling in Immunological Tolerance: Taming Good and Evil
Current Immunology Reviews (Discontinued) Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design SIRT1 Promotes Neuronal Fortification in Neurodegenerative Diseases through Attenuation of Pathological Hallmarks and Enhancement of Cellular Lifespan
Current Neuropharmacology Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Polyphenols: Well Beyond The Antioxidant Capacity: Gallic Acid and Related Compounds as Neuroprotective Agents: You are What You Eat!
Current Pharmaceutical Biotechnology Proteomic Analysis of Phosphorylation in the Brain
Current Proteomics The Role of Tec Family Kinases in Inflammatory Processes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Glutamate and Multiple Sclerosis
Current Medicinal Chemistry Visualising Neuroinflammation in Post-Stroke Patients: A Comparative PET Study with the TSPO Molecular Imaging Biomarkers [<sup>11</sup>C]PK11195 and [<sup>11</sup>C]vinpocetine
Current Radiopharmaceuticals